PR Newswire
PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13 th at 12:00 pm ET .
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com .
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-302135910.html
SOURCE Carisma Therapeutics Inc.
